Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Intraparenchymal Umbilical Cord Mesenchymal Stem Cell Transplantation in Patients with Subacute Ischemic Stroke: A Preliminary Study of Safety and Early Clinical Outcomes

The Indonesian Biomedical Journal · Vol. 18 No. 5 (2026) · hlm. 461–468

DOI
10.18585/inabj.v18i5.4281
ISSN
2085-3297, 2355-9179
Terbit
2026-11-14
Penerbit
Secretariat of The Indonesian Biomedical Journal
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc/4.0/

Abstrak

BACKGROUND: Intravenous thrombolysis and mechanical thrombectomy are current standard treatments for ischemic stroke, however their narrow therapeutic window limits eligibility for many patients. Umbilical cord-derived mesenchymal stem cells (UC-MSCs) have emerged as a promising regenerative therapy, but their safety and efficacy need to be further elucidated. Interleukin-6 (IL-6) and brain-derived neurotrophic factor (BDNF) may provide biological insights into the inflammatory and neuroregenerative responses following UC-MSC transplantation. This study was conducted to evaluate the safety and preliminary efficacy, including IL-6 and BDNF level, after stereotactic intraparenchymal UC-MSC transplantation.METHODS: Subjects with subacute ischemic stroke received stereotactic intraparenchymal transplantation of 2×10⁷ allogeneic UC-MSCs into the perolesional ischemic area, 13 to 20 days after stroke onset. Safety was assessed by monitoring the adverse events. Early efficacy was evaluated using the National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), Magnetic Resonance Imaging (MRI), and serum biomarkers, including IL-6 and BDNF. Serum IL-6 levels were measured using electrochemiluminescence immunoassay (ECLIA), while BDNF levels were measured using enzyme-linked immunosorbent assay (ELISA).RESULTS: No serious adverse events related to UC-MSCs administration were observed during the three-month follow-up. No serious adverse events related to UC-MSC administration were observed during the three-month follow-up. From baseline to the third month, improved mRS and NIHSS scores were observed (mean Δ: −0.75 and +4.00, respectively), along with reduced IL-6 (mean Δ: −2.76 pg/mL) and increased BDNF (mean Δ: +3.16 ng/mL).CONCLUSION: UC-MSC transplantation was well tolerated, with improvements in NIHSS and mRS and favorable changes in IL-6 and BDNF levels. These findings suggest that direct intraparenchymal UC-MSCs transplantation may be safe, as no severe adverse events were observed in this preliminary study.KEYWORDS: ischemic stroke, umbilical cord-derived mesenchymal stem cells (UC-MSCs), interleukin-6, brain-derived neurotrophic factor

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 157 tautan kepenulisan bersama · 93 lintas organisasi · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Hasanuddin University
  • Padjadjaran University
  • PT Prodia StemCell Indonesia (Indonesia)
  • Udayana University
  • University of Indonesia
  • Maranatha Christian University
  • IPB University
  • Organisasi lain
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Anna MeilianaPadjadjaran University89
Nurrani Mustika DewiPadjadjaran University45
Suryani As’ádHasanuddin University14
Yani LinaHasanuddin University6
Gatot Susilo LawrenceHasanuddin University6
Albertus Budi SulistyaPadjadjaran University6
Geofanny FaciciliaPT Prodia StemCell Indonesia (Indonesia)6
Yussy Afriani DewiPadjadjaran University6
Ilhamjaya PatellongiHasanuddin University4
Anwar SantosoUdayana University4
Syakib BakriHasanuddin University4
Melisa Intan BarlianaPadjadjaran University4
Keri Lestari DandanPadjadjaran University4
Mawar SubangkitIPB University4
Teguh RanakusumaUniversity of Indonesia3
Irawan YusufHasanuddin University3
Trilis YuliantiHasanuddin University3
Ida Paulina SorminHasanuddin University3
Erizal SugionoHasanuddin University3
Bayu Winata PuteraHasanuddin University3
Indriyanti Rafi SukmawatiHasanuddin University3
Wahyu WidowatiMaranatha Christian University2
Yenny SurjawanHasanuddin University2
Irma Ruslina DefiPadjadjaran University2
Mansyur AriefHasanuddin University2
Andri HidayatHasanuddin University2
Ferry SandraUniversitas Trisakti2
Marsetio DonosepoetroUniversitas Airlangga2
Irma Rahayu LatarissaPadjadjaran University2
Rina TrianaPadjadjaran University2
Angliana ChouwPT Prodia StemCell Indonesia (Indonesia)2

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S2764892910, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Intraparenchymal Umbilical Cord Mesenchymal Stem Cell Transplantation in Patients with Subacute Ischemic Stroke: A Preliminary Study of Safety and Early Clinical Outcomes</dc:title><dc:creator>Muhammad Agus Aulia</dc:creator><dc:creator>Keri Lestari</dc:creator><dc:creator>Ahmad Faried</dc:creator><dc:creator>Cynthia Retna Sartika</dc:creator><dc:creator>Andi Wijaya</dc:creator><dc:creator>Rima Haifa</dc:creator><dc:creator>Erin Triani</dc:creator><dc:creator>Nisa Zulfani</dc:creator><dc:creator>Rafa Fauziah</dc:creator><dc:subject>human umbilical cord mesenchymal stem cells</dc:subject><dc:subject>subacute ischemic stroke</dc:subject><dc:subject>interleukin-6</dc:subject><dc:subject>brain-derived neurotrophic factor</dc:subject><dc:subject>neuroinflammation</dc:subject><dc:subject>nerve regeneration</dc:subject><dc:subject>transplant safety</dc:subject><dc:subject>functional outcome</dc:subject><dc:subject>stroke rehabilitation</dc:subject><dc:subject>allogeneic stem cells</dc:subject><dc:description xml:lang="en">BACKGROUND: Intravenous thrombolysis and mechanical thrombectomy are current standard treatments for ischemic stroke, however their narrow therapeutic window limits eligibility for many patients. Umbilical cord-derived mesenchymal stem cells (UC-MSCs) have emerged as a promising regenerative therapy, but their safety and efficacy need to be further elucidated. Interleukin-6 (IL-6) and brain-derived neurotrophic factor (BDNF) may provide biological insights into the inflammatory and neuroregenerative responses following UC-MSC transplantation. This study was conducted to evaluate the safety and preliminary efficacy, including IL-6 and BDNF level, after stereotactic intraparenchymal UC-MSC transplantation.METHODS: Subjects with subacute ischemic stroke received stereotactic intraparenchymal transplantation of 2×10⁷ allogeneic UC-MSCs into the perolesional ischemic area, 13 to 20 days after stroke onset. Safety was assessed by monitoring the adverse events. Early efficacy was evaluated using the National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), Magnetic Resonance Imaging (MRI), and serum biomarkers, including IL-6 and BDNF. Serum IL-6 levels were measured using electrochemiluminescence immunoassay (ECLIA), while BDNF levels were measured using enzyme-linked immunosorbent assay (ELISA).RESULTS: No serious adverse events related to UC-MSCs administration were observed during the three-month follow-up. No serious adverse events related to UC-MSC administration were observed during the three-month follow-up. From baseline to the third month, improved mRS and NIHSS scores were observed (mean Δ: −0.75 and +4.00, respectively), along with reduced IL-6 (mean Δ: −2.76 pg/mL) and increased BDNF (mean Δ: +3.16 ng/mL).CONCLUSION: UC-MSC transplantation was well tolerated, with improvements in NIHSS and mRS and favorable changes in IL-6 and BDNF levels. These findings suggest that direct intraparenchymal UC-MSCs transplantation may be safe, as no severe adverse events were observed in this preliminary study.KEYWORDS: ischemic stroke, umbilical cord-derived mesenchymal stem cells (UC-MSCs), interleukin-6, brain-derived neurotrophic factor</dc:description><dc:publisher>Secretariat of The Indonesian Biomedical Journal</dc:publisher><dc:date>2026-11-14</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>https://doi.org/10.18585/inabj.v18i5.4281</dc:identifier><dc:identifier>10.18585/inabj.v18i5.4281</dc:identifier><dc:source>The Indonesian Biomedical Journal; Vol 18 No 5 (2026); 461-468</dc:source><dc:source>2085-3297</dc:source><dc:source>2355-9179</dc:source><dc:language>en</dc:language><dc:relation>https://inabj.org/index.php/ibj/article/download/4281/872</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc/4.0/</dc:rights></oai_dc:dc>